Latest Stories
Featured Stories
Explore inspiring journeys of recovery and resilience as patients share their experiences with Padaav’s root-cause-focused, evidence-based Ayurvedic treatments, highlighting the power of personalized care and holistic healing.
Feedback
All Stories
Delve into the heartfelt experiences of patients who have transformed their health and lives with Padaav’s research-backed Ayurvedic care, showcasing the impact of addressing root causes for lasting recovery.
Hamad Alam
Rectal Adenocarcinoma
New Delhi
Hamad’s struggle reached a terrifying peak in 2018 while traveling back to Delhi from a cou…
Shilipi
Acute Recurrent Pancreatitis
Kotdwar, Uttarakhand.
Shilpi’s struggle began suddenly during her 10th-grade school break, when she felt a sharp …
Anurag Goyal
Investment Banker
New Delhi
Anurag’s struggle began suddenly in the midnight of September 2010, when he experienced exc…
Sumit Kumar
Pancreas Divisum with secondary Chronic Pancreatitis
Dehradun, Uttarakhand
Sumit suffered from Pancreas Divisum, a congenital anomaly where the two pancreatic ducts (the ve…
Aviral Saxena
Chronic Pancreatitis with Secondary Diabetes
Dehradun, Uttarakhand
Aviral’s journey began in November 2022 while he was actively working as a freelancer. The …
Rajeev Sharma
Chronic Pancreatitis
Dehradun, Uttarakhand
Rajeev’s journey began with mild symptoms in 2009, potentially following a physical encount…
Research
Our Research
At Padaav, alongside delivering unparalleled patient care and promoting holistic health, we are committed to advancing Ayurveda by actively participating in research and contributing to its growing body of knowledge.
Response to Ayurvedic therapy in the treatment of migraine without aura
A study on 204 migraine patients using an Ayurvedic Treatment Protocol (AyTP) showed 35.2% had complete relief, 35.2% had mild episodes without medication, and 70.5% experienced reduced pain frequency and intensity. The preliminary results suggest the AyTP may be effective, though the study's design limits firm conclusions.
Treatment of relapsed undifferentiated acute myeloid leukemia (AML-M0) with Ayurvedic therapy
A 16-year-old boy with AML-M0 relapsed after chemotherapy in 1997. He opted for Ayurvedic therapy (AYT) instead of further treatment. After six months, he was in remission and continued AYT for five years, with intermittent maintenance for two years. He has been disease-free and healthy for 12 years.
Case studies on prophylactic ayurvedic therapy in migraine patients
Ayurvedic treatment has shown effectiveness in managing migraines. A protocol (ATP) with herbo-mineral formulations, regular meals, and sleep reduced migraine frequency and intensity in a study of nine patients. Five reported significant improvement after 120 days, with no serious side effects. Ongoing research is further validating the findings.
Herbo-mineral ayurvedic treatment in a high risk acute promyelocytic leukemia patient with second relapse: 12 years follow up
A 47-year-old diabetic male with high-risk AML-M3 relapsed after multiple chemotherapy treatments. In 1997, he opted for a pilot Ayurvedic study and was treated with Navajeevan, Kamadudha Rasa, and Keharuba Pisti. He achieved complete remission and has remained disease-free for 13 years without side effects from the alternative treatment.
Sustainable Effect of Ayurvedic Formulations in the Treatment of Nutritional Anemia in Adolescent Students
This study evaluated the impact of Ayurvedic treatments (Sootshekhar Rasa and Sitopaladi Churna) on nutritional anemia in 1322 adolescent students in Dehradun. After 90 days of treatment, significant hemoglobin improvements were seen in the treatment groups, especially those receiving a daily dose of 250 mg SR and 400 mg SC. The study concluded that this combination effectively improves anemia in adolescents without adverse effects.
Acute and Sub acute Toxicity Study of Ayurvedic Formulation (AYFs) Used for Migraine Treatment
This study tested the safety of five Ayurvedic formulations for migraine prevention in rats and mice. Acute and sub-acute toxicity studies showed no toxic effects at doses up to 10 times the human dose. A slight mortality in high-dose groups was unrelated to treatment. The formulations are considered safe, but further chronic toxicity studies are needed.